[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Taysha Gene Therapies Inc 3000 Pegasus Park Dr. Ste 1430 DALLAS TX 75247 USA

www.tayshagtx.com Employees: 99 P: 214-612-0000

Sector:

Medical

Description:

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.

Key Statistics

Overview:

Market Capitalization, $K 1,712,672
Enterprise Value, $K 1,442,562
Shares Outstanding, K 287,361
Float, K 276,499
% Float 96.22%
Short Interest, K 40,051
Short Float 13.94%
Days to Cover 14.00
Short Volume Ratio 0.52
% of Insider Shareholders 3.78%
% of Institutional Shareholders 77.70%

Financials:

Annual Sales, $ 9,770 K
Annual Net Income, $ -109,000 K
Last Quarter Sales, $ 5,490 K
Last Quarter Net Income, $ -27,850 K
EBIT, $ -110,490 K
EBITDA, $ -109,340 K

Growth:

1-Year Return 101.85%
3-Year Return 705.95%
5-Year Return -72.45%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 90.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.12 on 05/06/26
Next Earnings Date 08/11/26
Earnings Per Share ttm -0.34
EPS Growth vs. Prev Qtr -50.00%
EPS Growth vs. Prev Year -50.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

TSHA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -56.07%
Return-on-Assets % -40.16%
Profit Margin % -1,115.66%
Debt/Equity 0.20
Price/Sales 185.24
Price/Cash Flow N/A
Price/Book 8.54
Book Value/Share 0.90
Interest Coverage -1,815.67
60-Month Beta 1.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.